Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2020 6
2021 3
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: from 2017/1/1 - 3000/12/12. Clear all
Page 1
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, Hanratty B, Adil M, Zhao J, Zaidi S, True LD, Sperger JM, Cheng HH, Yu EY, Montgomery RB, Hawley JE, Ha G, Lee JK, Harmon SA, Corey E, Lang JM, Sawyers CL, Morrissey C, Schweizer MT, Gulati R, Nelson PS, Haffner MC. Ajkunic A, et al. Among authors: hawley je. Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3745991. doi: 10.21203/rs.3.rs-3745991/v1. Res Sq. 2023. PMID: 38196594 Free PMC article. Preprint.
To fully capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the target proteins in tumor tissues is required. In castration-resistant prostate cancer (CRPC), agents targeting prostate-sp …
To fully capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the expression patterns of the tar …
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, McKiernan J, Anderson CB, Decastro GJ, Weintraub J, Virk R, Lowy I, Hu J, Chaimowitz MG, Guo XV, Zhang Y, Haffner MC, Worley J, Stein MN, Califano A, Drake CG. Hawley JE, et al. Cancer Cell. 2023 Nov 13;41(11):1972-1988.e5. doi: 10.1016/j.ccell.2023.10.006. Epub 2023 Nov 2. Cancer Cell. 2023. PMID: 37922910 Free article.
When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While androgen deprivation therapy (ADT) induces a complex immune infiltrate in localized …
When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRP …
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Hoffman-Censits J, Grivas P, Powles T, Hawley J, Tyroller K, Seeberger S, Guenther S, Jacob N, Mehr KT, Hahn NM. Hoffman-Censits J, et al. Among authors: hawley j. Future Oncol. 2024 Feb;20(4):179-190. doi: 10.2217/fon-2023-0492. Epub 2023 Sep 6. Future Oncol. 2024. PMID: 37671748 Free article.
Urothelial cancer is called advanced when it has spread outside of the urinary tract. Chemotherapy is often the first main treatment given to people with advanced urothelial cancer. Avelumab is an immunotherapy drug that can help the body's immune system find and de …
Urothelial cancer is called advanced when it has spread outside of the urinary tract. Chemotherapy is often the first main treatment …
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Sayar E, et al. Among authors: hawley je. JCI Insight. 2023 Apr 10;8(7):e162907. doi: 10.1172/jci.insight.162907. JCI Insight. 2023. PMID: 36821396 Free PMC article.
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited dat
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
Miyahira AK, Hawley JE, Adelaiye-Ogala R, Calais J, Nappi L, Parikh R, Seibert TM, Wasmuth EV, Wei XX, Pienta KJ, Soule HR. Miyahira AK, et al. Among authors: hawley je. Prostate. 2023 Feb;83(3):207-226. doi: 10.1002/pros.24461. Epub 2022 Nov 28. Prostate. 2023. PMID: 36443902 Review.
INTRODUCTION: The 2022 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Exploring New Frontiers in Prostate Cancer Research," was held from June 23 to 26, 2022, at the University of California, Los Angeles, Luskin Conference Center, in Los Angel …
INTRODUCTION: The 2022 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Exploring New Frontiers in Prostate C
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS. Guo C, et al. Among authors: hawley je. Eur Urol. 2023 Mar;83(3):224-238. doi: 10.1016/j.eururo.2022.09.004. Epub 2022 Sep 13. Eur Urol. 2023. PMID: 36114082 Free article.
Mechanisms driving differences in B7-H3 expression across genomic subsets warrant investigation for understanding the role of B7-H3 in cancer growth and for the clinical development of B7-H3 targeted therapies. PATIENT SUMMARY: B7-H3, a protein expressed on the surface of …
Mechanisms driving differences in B7-H3 expression across genomic subsets warrant investigation for understanding the role of B7-H3 in ca
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Shah NJ, Patel VG, Zhong X, Pina L, Hawley JE, Lin E, Gartrell BA, Febles VA, Wise DR, Qin Q, Mellgard G, Joshi H, Nauseef JT, Green DA, Vlachostergios PJ, Kwon DH, Huang F, Liaw B, Tagawa S, Kantoff P, Morris MJ, Oh WK. Shah NJ, et al. Among authors: hawley je. JNCI Cancer Spectr. 2022 May 2;6(3):pkac035. doi: 10.1093/jncics/pkac035. JNCI Cancer Spectr. 2022. PMID: 35657341 Free PMC article.
BACKGROUND: TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. ...However, the impact of ADT on severe …
BACKGROUND: TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a ne …
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.
Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP; COVID-19 and Cancer Consortium (CCC19). Fu J, et al. Among authors: hawley je. JAMA Netw Open. 2022 Mar 1;5(3):e224304. doi: 10.1001/jamanetworkopen.2022.4304. JAMA Netw Open. 2022. PMID: 35344045 Free PMC article.
OBJECTIVE: To investigate racial disparities in severity of COVID-19 presentation, clinical complications, and outcomes between Black patients and non-Hispanic White patients with cancer and COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This retr …
OBJECTIVE: To investigate racial disparities in severity of COVID-19 presentation, clinical complications, and outcomes betwee …
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C; COVID-19 and Cancer Consortium (CCC19). Hawley JE, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142046. doi: 10.1001/jamanetworkopen.2021.42046. JAMA Netw Open. 2022. PMID: 34982158 Free PMC article.
Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were associated with geography. OBJECTIVE: To quantify spatiotemporal variation in CO
Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVI
COVID-19 vaccination and breakthrough infections in patients with cancer.
Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, Blau S, Daher A, El Zarif T, Friese CR, Griffiths EA, Hawley JE, Hayes-Lattin B, Karivedu V, Latif T, Mavromatis BH, McKay RR, Nagaraj G, Nguyen RH, Panagiotou OA, Portuguese AJ, Puc M, Santos Dutra M, Schroeder BA, Thakkar A, Wulff-Burchfield EM, Mishra S, Farmakiotis D, Shyr Y, Warner JL, Choueiri TK; COVID-19 and Cancer Consortium. Schmidt AL, et al. Among authors: hawley je. Ann Oncol. 2022 Mar;33(3):340-346. doi: 10.1016/j.annonc.2021.12.006. Epub 2021 Dec 24. Ann Oncol. 2022. PMID: 34958894 Free PMC article.
As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccinat …
As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active …
19 results